HU, OLIVER YOA PU,胡幼圃,胡幼圃,YANG, PING,杨苹,楊蘋,HSIONG, CHENG HUEI,熊正辉,熊正輝
申请号：
TW107136936
公开号：
TW202015702A
申请日:
2018.10.19
申请国别(地区):
TW
年份:
2020
代理人:
摘要：
A galactose oral composition comprising galactose, and a buffer solution； wherein the galactose oral composition contains 1% to 80% by weight of galactose. The antioxidant is selected from the group consisting of Vitamin A, Vitamin C, Vitamin E, sodium bisulfite, flavonoids, polyphenols, Ethylenediaminetetraacetic acid (EDTA), Diethylenetriaminepentaacetic acid (DTPA), and NTA-Nitrilotriacetate acid (NTA). The buffer solution is selected from the group consisting of citrate buffer, phosphate buffer, acetate buffer, carbonate buffer, ascorbic acid buffer, and triethanolamine buffer. The galactose oral composition can be applied to detect individual galactose removal ability to assess liver function.一種半乳糖口服組合物，包含半乳糖、緩衝液及抗氧化劑，其中半乳糖含量重量百分比為1%至80%；其中該抗氧化劑係選自維生素C、亞硫酸氫鈉(sodium bisulfite)、維生素A、維生素E、類黃酮、多酚、乙二胺四乙酸((Ethylenediaminetetraacetic acid(EDTA))、二乙烯三胺五乙酸(DTPA)、N,N-雙[羧甲基]甘胺酸(NTA)所組成的群組；其中該緩衝液係選自於由檸檬酸緩衝液(citrate buffer)、磷酸緩衝液(phosphate buffer)、醋酸緩衝液(acetate buffer)、碳酸緩衝液(carbonate buffer)及三乙醇胺緩衝液(triethanolamine buffer)所組成的群組；該半乳糖口服組合物可以應用偵測個體半乳糖去除能力以評估肝臟功能。
